State of the Biopharmaceutical Industry 2023
Accessing in-depth insights from the ‘State of the Biopharmaceutical Industry’ report will help you –
- Examine the current attitudes of business leaders towards the emerging trends impacting the biopharmaceutical industry in the next 12 months.
- Understand the most impactful emerging technologies – Industry, Regulatory and Macroeconomic factors that are going to impact and dominate the industry throughout 2023.
- Identify the most impactful anticipated regulatory approvals and drug launches in the industry in 2023, highlight top-selling drugs (2022 vs 2023), and overview the clinical trials landscape for 2023.
- Uncover the healthcare industry professionals’ sentiment about the industry’s growth prospects during the next 12 months and how this sentiment changed over the past 3 years.
How is the ‘State of the Biopharmaceutical Industry’ report different from other reports in the market?
- It measures which themes are going to have the greatest positive or negative impact on the pharmaceutical industry in 2023.
- It provides a qualitative analysis of the top regions (Europe, North America, and APAC).
- It analyzes key emerging trends (regulatory and macroeconomic trends) as well as emerging technologies.
- The State of the Biopharmaceutical Industry report highlights the planned clinical trials, projected clinical trails completions, top-selling drugs, and drug launches that are going to happen in 2023.
- Understand other topics that GlobalData identified as important for you (Inflation Reduction Act, prospects of deflation, the rise of ESG, and reshoring of pharmaceutical manufacturing) and adjust your business development strategies.
We recommend this valuable source of information to anyone involved in:
- Pharmaceutical Companies
- Biotech
- CMOs, CMOs, and CDMOs
- Consulting Companies
- Technology Companies and Start-ups
- Professional Services (e.g., Investment, Equity Companies, Banks)
To Get a Snapshot of the State of the Biopharmaceutical Industry Report, Download a Free Report Sample
State of the Biopharmaceutical Industry Report Overview
The pharmaceutical industry has long been labeled as recession-proof, as medicines are essential products that cannot be completely replaced. However, the looming global recession is likely to have implications on healthcare budgets, forcing governments and regulators to put more stringent laws in place around drug pricing and market access. At the same time, the pharmaceutical industry will have to deal with increased drug development costs that will affect their margins.
The state of the biopharmaceutical industry research report examines the business environment and trends that are going to shape the biopharmaceutical industry in 2023. The report highlights the most impactful emerging technologies, industry, regulatory, and macroeconomic factors that are going to impact and dominate the industry throughout 2023.
Key Findings of the Biopharmaceutical Industry
In 2023, businesses will face turbulent times, and the pharmaceutical industry is not an exception. Financial and costs pressures, as well as increasing regulations and an uncertain economic outlook will be contributing to decreased levels of optimism in growth prospects. To sustain growth, the pharmaceutical industry will need to innovate.
Furthermore, to remain competitive, businesses need to ensure integration, cost-effectiveness, efficiency, and customer excellence, as well as to attain innovative solutions and investor support. Vertical integration, patent expiry of biologics, mega M&As, and ESG factors are anticipated to have the greatest positive impact on the pharmaceutical industry. In addition, big data and AI will continue to dominate as transformational forces in the healthcare sector in 2023.
Emerging Industry Trends in the Biopharmaceutical Industry
The key emerging industry trends in the biopharmaceutical industry are genomics, immuno-oncology drug development, personalized/precision medicine, real-world evidence, remote patient monitoring, electronic health records, biosimilar uptake, decentralized/virtual clinical trials, digital therapeutics, and patient empowerment among others. Genomics is identified as the top emerging pharmaceutical industry trend for 2023.
Biopharmaceutical Industry Analysis, by Emerging Trends, 2023 (%)
For more emerging trend insights in the biopharmaceutical industry, download a free report sample
Emerging Technologies in the Biopharmaceutical Industry
The key emerging technologies impacting the biopharmaceutical industry are AI, big data, cybersecurity, digital media, social media, virtual and augmented reality, IoT, robotics, application programming interfaces, cloud computing, 3-D printing, and blockchain among others. Across all geographies, AI, followed by big data are expected to have the biggest impact on the pharmaceutical industry in 2023.
Biopharmaceutical Industry, by Emerging Technologies, 2023 (%)
For more emerging technology insights in the biopharmaceutical industry, download a free report sample
Biopharmaceutical Industry Value Chain
The value chain of the biopharmaceutical industry includes supply chain, drug development, end-user experience, physician-targeted sales and marketing, drug discovery, manufacturing, and patient-targeted sales and marketing. Supply chain and manufacturing will be impacted the most by inflation in 2023.
Therapy Areas in the Biopharmaceutical Industry
The top therapy areas for planned clinical trials to be initiated in 2023 in the biopharmaceutical industry are oncology, central nervous system, infectious disease, cardiovascular, gastrointestinal, metabolic disorders, respiratory, immunology, musculoskeletal disorders, and dermatology. Oncology trials will outnumber CNS and infectious disease trials.
Biopharmaceutical Industry, by Therapy Areas (To be Initiated in 2023, %)
For more insights on the therapy areas in the biopharmaceutical industry, download a free report sample
Biopharmaceutical Industry – Competitive Landscape
Top industry sponsors for trials projected to be completed in 2023 are AstraZeneca, Novartis, Johnson & Johnson (J&J), F Hoffman La Roche, Pfizer, Eli Lily, Merck, Abbvie, and GSK among others. AstraZeneca, Novartis, and Johnson & Johnson (J&J) will likely complete the most industry trials in 2023.
Biopharmaceutical Industry, by Industry Sponsors, 2023 (%)
For more industry sponsor insights in the biopharmaceutical industry, download a free report sample
Biopharmaceutical Industry Report Overview
| Key Emerging Trends | Genomics, Immuno-Oncology Drug Development, Personalized/Precision Medicine, Real-World Evidence, Remote Patient Monitoring, Electronic Health Records, Biosimilar Uptake, Decentralized/Virtual Clinical Trials, Digital Therapeutics, and Patient Empowerment |
| Key Emerging Technologies | AI, Big Data, Cybersecurity, Digital Media, Social Media, Virtual and Augmented Reality, IoT, Robotics, Application Programming Interfaces, Cloud Computing, 3-D Printing, and Blockchain |
| Key Value Chain | Supply Chain, Drug Development, End-User Experience, Physician-Targeted Sales and Marketing, Drug Discovery, Manufacturing, and Patient-Targeted Sales and Marketing |
| Key Therapy Areas | Oncology, Central Nervous System, Infectious Disease, Cardiovascular, Gastrointestinal, Metabolic Disorders, Respiratory, Immunology, Musculoskeletal Disorders, and Dermatology |
| Key Industry Sponsors | AstraZeneca, Novartis, Johnson & Johnson (J&J), F Hoffman La Roche, Pfizer, Eli Lily, Merck, Abbvie, and GSK |
Biopharmaceutical Industry Therapy Areas Outlook (2023)
- Oncology
- Central Nervous System
- Infectious Disease
- Cardiovascular
- Gastrointestinal
- Metabolic Disorders
- Respiratory
- Immunology
- Musculoskeletal Disorders
- Dermatology
Scope
This report provides:
- A snapshot of current attitudes of business leaders toward the emerging industry trends and how they are shaping the future of the healthcare industry
- Overview of the hindrances and drivers that will affect the state of the biopharmaceutical industry
- Emerging technologies that are expected to have the greatest impact on the biopharmaceutical industry in the next 12 months
- Executives’ opinions on the growth prospects of the biopharmaceutical industry over the next 12 months
- Key industry shake-ups and trends to watch that represent both challenges and opportunities to the industry
Reasons to Buy
- Stay up to date with the major emerging technologies and regulatory, macroeconomic, and industry trends that will impact the pharmaceutical industry in 2023.
- Explore how the biopharmaceutical landscape has changed
- Identify the most impactful anticipated regulatory approvals and drug launches in the industry in 2023
- Gain insight into the regulatory and microeconomics trends that will have positive and negative effects on the biopharmaceutical industry
- Identify emerging industry trends and innovations to gain a competitive advantage
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
The key emerging industry trends in the biopharmaceutical industry are genomics, immuno-oncology drug development, personalized/precision medicine, real-world evidence, remote patient monitoring, electronic health records, biosimilar uptake, decentralized/virtual clinical trials, digital therapeutics, and patient empowerment.
The key emerging technologies in the biopharmaceutical industry are AI, big data, cybersecurity, digital media, social media, virtual and augmented reality, IoT, robotics, application programming interfaces, cloud computing, 3-D printing, and blockchain.
The value chain of the biopharmaceutical industry includes supply chain, drug development, end-user experience, physician-targeted sales and marketing, drug discovery, manufacturing, and patient-targeted sales and marketing.
The key therapy areas in the biopharmaceutical industry are oncology, central nervous system, infectious disease, cardiovascular, gastrointestinal, metabolic disorders, respiratory, immunology, musculoskeletal disorders, and dermatology.
The key industry sponsors in the biopharmaceutical industry are AstraZeneca, Novartis, Johnson & Johnson (J&J), F Hoffman La Roche, Pfizer, Eli Lily, Merck, Abbvie, and GSK.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Still undecided about purchasing this report?
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Related reports
View more Pharmaceuticals reports